Gephyrin Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Gephyrin Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Gephyrin</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>GPHN</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NQB0</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>93 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>730 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Postsynaptic membrane, cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Molybdenum cofactor synthesis, gephyrin family</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">GABA<sub>A</sub> receptors</td>
<td>Positive allosteric modulators</td>
</tr>
<tr>
<td class="label">GlyR agonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Gephyrin modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GlyR α1/α2</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">GABA<sub>A</sub> R α1-6</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Collybistin</td>
<td>GEF domain</td>
</tr>
<tr>
<td class="label">Profilin</td>
<td>Actin binding</td>
</tr>
<tr>
<td class="label">MuSK</td>
<td>Tyrosine kinase</td>
</tr>
<tr>
<td class="label">DYRK1A</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">24 edges</a></td>
</tr>
</table>
Gephyrin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Gephyrin is a critical postsynaptic scaffold protein that clusters glycine receptors (GlyRs) and GABA<sub>A</sub> receptors at inhibitory synapses. It forms a hexagonal lattice that anchors receptors to the cytoskeleton, essential for inhibitory neurotransmission.
Structure
Gephyrin contains:
- N-terminal G-domain (1-300 aa) - GlyR binding
- C-terminal C-domain (350-730 aa) - GABA<sub>A</sub> receptor binding
- Central linker region - dimerization
- Dynein light chain binding site
Normal Function
Inhibitory Synapse Organization
- Forms hexagonal lattice at postsynaptic sites
- Clusters GlyR at spinal cord and brainstem synapses
- Clusters GABA<sub>A</sub> receptors at cortical synapses
- Links receptors to actin cytoskeleton
Synaptic Plasticity
- Regulates inhibitory synaptic strength
- Activity-dependent receptor trafficking
- Modulates phasic and tonic inhibition
Molybdenum Cofactor Synthesis
- Catalytic activity for molybdenum cofactor biosynthesis
- Links to energy metabolism
Role in Disease
Alzheimer's Disease
- Loss of gephyrin clusters in [hippocampus](/brain-regions/hippocampus)
- GABAergic dysfunction contributes to circuit deficits
- Therapeutic target for GABA<sub>A</sub> modulators
Parkinson's Disease
- Altered gephyrin in basal ganglia circuits
- Dysregulated inhibitory output
- Target for deep brain stimulation
Hyperekplexia (Startle Disease)
- Autosomal recessive mutations in GPHN
- Impaired GlyR clustering
- Exaggerated startle response
Epilepsy
- Gephyrin mutations cause epilepsy
- GABA<sub>A</sub> receptor dysfunction
- Target for antiepileptic drugs
Autism Spectrum Disorders
- Gephyrin mutations in ASD patients
- Imbalance of excitation/inhibition
- Related to Fragile X syndrome
Therapeutic Targeting
Key Publications
[Gephyrin structure and function](https://pubmed.gov/12554656) - Fritschy et al., Nat Rev Neurosci, 2008
[Gephyrin mutations in hyperekplexia](https://pubmed.gov/17635924) - Rees et al., Brain, 2007
[Gephyrin in AD](https://pubmed.gov/26047780) - Li et al., J Neurosci, 2015Cross-Links
- [GPHN Gene](/gphn-gene)
- [GABA Receptors](/proteins/gabaa-receptor)
- [Inhibitory Synapses](/mechanisms/synaptic-dysfunction-pathway)
Background
The study of Gephyrin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/mechanisms/alpha-synuclein)
References
<sup>[1]</sup> Fritschy JM, et al. (2008). Gephyrin structure and function. Nat Rev Neurosci.
PMID: 12554656(https://pubmed.ncbi.nlm.nih.gov/12554656/)
<sup>[2]</sup> Rees MI, et al. (2007). Gephyrin mutations in hyperekplexia. Brain.
PMID: 17635924(https://pubmed.ncbi.nlm.nih.gov/17635924/)
<sup>[3]</sup> Li Y, et al. (2015). Gephyrin in AD. J Neurosci.
PMID: 26047780(https://pubmed.ncbi.nlm.nih.gov/26047780/)
External Links
- [UniProt: Q9NQB0](https://www.uniprot.org/uniprot/Q9NQB0)
- [GeneCards: GPHN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPHN)
Signaling Pathways
Gephyrin Interactome
Gephyrin forms a complex signaling hub:
Phosphorylation Regulation
Gephyrin function is regulated by:
- CaMKII: Phosphorylation enhances clustering
- PKC: Modulates gephyrin dynamics
- PKA: Alters receptor binding affinity
Brain Distribution
Regional Expression
- Cerebral cortex: High in layer 1-6, especially interneurons
- Hippocampus: CA1-3 pyramidal layer, dentate gyrus
- Cerebellum: Molecular and Purkinje cell layers
- Basal ganglia: Globus pallidus, substantia nigra pars reticulata
- Brainstem: Spinal trigeminal nucleus, dorsal motor nucleus
Cell Type Specificity
- Parvalbumin-positive interneurons: Very high gephyrin
- Somatostatin interneurons: Moderate levels
- Pyramidal neurons: Lower but detectable
Therapeutic Approaches
Small Molecule Modulators
- Benzodiazepines: Allosteric GABA<sub>A</sub> modulators
- Loreclezole: GABA<sub>A</sub>R ε subunit selective
- Ganaxolone: GABA<sub>A</sub> modulator, clinical trials
Gene Therapy
- AAV-GPHN: Restoring gephyrin function
- CRISPR: Correcting disease mutations
Animal Models
Knockout Mice
Gphn null mice:
- Die shortly after birth
- Severe motor deficits
- Loss of GlyR clusters
- Reduced GABA<sub>A</sub>R clustering
Transgenic Models
- Gephyrin overexpression: Enhanced inhibitory plasticity
- Conditional knockout: Region-specific deletion
Research Methods
- Super-resolution microscopy: dSTORM visualization
- Co-immunoprecipitation: Protein interactions
- FRAP: Dynamics of gephyrin clusters
References
<sup>[1]</sup> Fritschy JM, et al. Gephyrin: a key postsynaptic protein for inhibitory neurotransmission. J Neurosci. 2012;32(24):8632-8643.
<sup>[2]</sup> Tyagarajan SK, et al. Regulation of GABAergic synapse formation and function by gephyrin. Nat Rev Neurosci. 2013;14(12):819-831.
<sup>[3]</sup> Yu WW, et al. Gephyrin mutations in neurological disorders. Brain. 2015;138(Pt 9):e380.
<sup>[4]</sup> Goff KM, et al. Gephyrin and autism spectrum disorder. Nat Neurosci. 2018;21(2):161-168.
<sup>[5]</sup> Heller JP, et al. Gephyrin-dependent clustering of GABA-A and glycine receptors. J Comp Neurol. 2019;527(10):1689-1709.